GlassScriptPhysician profile
Kaycee P Frederick
NPI 1457721243
$16,708.17
in general payments reported to CMS, 2019-2025
31 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2022: $3,206 · 2023: $6,249 · 2024: $4,328 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,480 · Consulting Fee: $3,325 · Travel and Lodging: $841 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,480.05 |
| Consulting Fee | $3,325.00 |
| Travel and Lodging | $840.69 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $4,390.16 | 2023-2024 | Sprint Pns System |
| Abbott Laboratories | $3,792.04 | 2021-2025 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $2,297.44 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Primeadvanced Surescan |
| Spinal Simplicity, LLC | $1,426.88 | 2022-2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $726.23 | 2021-2025 | Nalu Neurostimulation System |
| Abbvie INC. | $558.79 | 2021-2025 | |
| Biotronik Nro, INC. | $483.13 | 2023-2024 | Prospera, Biotronik |
| Nevro Corp. | $478.20 | 2021-2024 | Senza |
| Pfizer INC. | $352.10 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $322.03 | 2022-2025 | Belbuca, Xtampza |
| Relievant Medsystems, INC. | $287.12 | 2021-2023 | Intracept |
| Boston Scientific Corporation | $278.64 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $242.07 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $184.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.20 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $128.00 | 2023-2024 | Mild Device Kit |
| Grt US Holding, INC. | $112.72 | 2022 | |
| Bioventus LLC | $102.98 | 2022-2023 | Stimrouter Implantable Kit |
| Hydrocision, INC. | $75.35 | 2023 | Tenjet |
| Biodelivery Sciences International, INC. | $63.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.72 | 2021 | |
| Averitas Pharma INC. | $42.28 | 2023-2024 | Qutenza |
| Scilex Pharmaceuticals INC. | $29.01 | 2022 | |
| Redhill Biopharma INC. | $24.91 | 2021 | |
| Amgen INC. | $24.78 | 2021 | |
| Forte Bio-Pharma LLC | $16.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.91 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.79 | 2023 | Iovera, Zilretta |
| Lilly USA, LLC | $13.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.58 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaycee Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.